C Ellis Wisely1, Mersiha Hadziahmetovic2, Rachel E Reem1, Erinn M Hade3, Subir Nag4, Frederick H Davidorf1, Douglas Martin5, Colleen M Cebulla1. 1. Department of Ophthalmology and Visual Science, Havener Eye Institute, The Ohio State University Wexner Medical Center, Columbus, OH. 2. Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH. 3. Center for Biostatistics, Department of Bioinformatics, The Ohio State University Wexner Medical Center, Columbus, OH. 4. Department of Radiation Oncology, Northern California Kaiser Permanente, Santa Clara, CA. 5. Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH. Electronic address: Douglas.Martin@osumc.edu.
Abstract
PURPOSE: To report our experience in long-term follow-up of ocular melanoma patients treated with custom OSU-Nag eye plaques using (125)I sources. METHODS: A retrospective chart review was conducted for 113 consecutive ocular melanoma patients with follow-up visual acuity data who were treated with OSU-Nag plaque episcleral brachytherapy at The Ohio State University Medical Center from 1994 to 2009. Visual acuity, complication data, and recurrence rates were recorded up to 120 months after brachytherapy. RESULTS: Median age at presentation was 63.0 years (range, 22-93). Median follow-up was 65.5 months (range, 2-180). Median radiation dose at the prescription point was 85.8 Gy (range, 51.8-103.7). Preservation of useful visual acuity, defined as better than 20/200, was noted in 43 of 74 (58%) of patients in the present study at 36 months compared with 50.1% of Collaborative Ocular Melanoma Study participants. By 120 months, 17 of 30 (57%; 95% confidence interval, 45-69%) progressed to visual acuity worse than 20/200, whereas 9 of 30 (30%) retained visual acuity of 20/40 or better, and 4 of 30 (13%) were 20/50-20/200. The rate of retinopathy after radiation was approximately 40% of all those observed by 60 months. Baseline visual acuity, apical tumor height, American Joint Committee on Cancer tumor category, and distance between the tumor and the fovea were all significantly associated with loss of visual acuity. The local tumor control rate by 60 months of follow-up was 93% (95% confidence interval, 85-97%). CONCLUSIONS: The OSU-Nag custom (125)I plaque is an effective treatment for uveal melanoma, with preservation of useful visual acuity in 58% of eyes 3 years after treatment and 43% of eyes 10 years after treatment.
PURPOSE: To report our experience in long-term follow-up of ocular melanomapatients treated with custom OSU-Nag eye plaques using (125)I sources. METHODS: A retrospective chart review was conducted for 113 consecutive ocular melanomapatients with follow-up visual acuity data who were treated with OSU-Nag plaque episcleral brachytherapy at The Ohio State University Medical Center from 1994 to 2009. Visual acuity, complication data, and recurrence rates were recorded up to 120 months after brachytherapy. RESULTS: Median age at presentation was 63.0 years (range, 22-93). Median follow-up was 65.5 months (range, 2-180). Median radiation dose at the prescription point was 85.8 Gy (range, 51.8-103.7). Preservation of useful visual acuity, defined as better than 20/200, was noted in 43 of 74 (58%) of patients in the present study at 36 months compared with 50.1% of Collaborative Ocular Melanoma Study participants. By 120 months, 17 of 30 (57%; 95% confidence interval, 45-69%) progressed to visual acuity worse than 20/200, whereas 9 of 30 (30%) retained visual acuity of 20/40 or better, and 4 of 30 (13%) were 20/50-20/200. The rate of retinopathy after radiation was approximately 40% of all those observed by 60 months. Baseline visual acuity, apical tumor height, American Joint Committee on Cancer tumor category, and distance between the tumor and the fovea were all significantly associated with loss of visual acuity. The local tumor control rate by 60 months of follow-up was 93% (95% confidence interval, 85-97%). CONCLUSIONS: The OSU-Nag custom (125)I plaque is an effective treatment for uveal melanoma, with preservation of useful visual acuity in 58% of eyes 3 years after treatment and 43% of eyes 10 years after treatment.
Authors: Lee M Jampol; Claudia S Moy; Timothy G Murray; Sandra M Reynolds; Daniel M Albert; Andrew P Schachat; Kenneth R Diddie; Robert E Engstrom; Paul T Finger; Kenneth R Hovland; Leonard Joffe; Karl R Olsen; Craig G Wells Journal: Ophthalmology Date: 2002-12 Impact factor: 12.079
Authors: Bradford A Perez; Pradeep Mettu; Lejla Vajzovic; Douglas Rivera; Ali Alkaissi; Beverly A Steffey; Jing Cai; Sandra Stinnett; Jonathan J Dutton; Edward G Buckley; Edward Halperin; Lawrence B Marks; Prithvi Mruthyunjaya; David G Kirsch Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-07 Impact factor: 7.038
Authors: Subir Nag; Dian Wang; Hong Wu; Constance J Bauer; Robert B Chambers; Frederick H Davidorf Journal: Int J Radiat Oncol Biol Phys Date: 2003-08-01 Impact factor: 7.038
Authors: Vinita Takiar; Dan S Gombos; Firas Mourtada; Laura A Rechner; Ann A Lawyer; William H Morrison; Adam S Garden; Beth M Beadle Journal: Pract Radiat Oncol Date: 2013-09-25
Authors: Timothy W Grosel; Matthew Karl; Robert T Pilarski; Frederick H Davidorf; Mohamed H Abdel-Rahman; Colleen M Cebulla Journal: Fam Cancer Date: 2021-01-06 Impact factor: 2.375
Authors: Tatiana A Slastnikova; Andrey A Rosenkranz; Natalia B Morozova; Maria S Vorontsova; Vasiliy M Petriev; Tatiana N Lupanova; Alexey V Ulasov; Michael R Zalutsky; Raisa I Yakubovskaya; Alexander S Sobolev Journal: Int J Nanomedicine Date: 2017-01-10
Authors: Michael Chang; Lauren A Dalvin; Mehdi Mazloumi; Andrei Martin; Antonio Yaghy; Xiaolu Yang; Saba Bakhtiari; Lucy Li; Erin Jennings; Arman Mashayekhi; Carol L Shields Journal: Asia Pac J Ophthalmol (Phila) Date: 2020 Jan-Feb
Authors: Andrew J Wong; Bin S Teh; Brandon T Nguyen; Ramiro Pino; Maria E Bretana; Eric H Bernicker; Patricia Chevez-Barrios; E Brian Butler; Amy C Schefler Journal: J Contemp Brachytherapy Date: 2022-04-11
Authors: H Michael Gach; Stacie L Mackey; Sana Rehman; Mo Kadbi; Jacqueline E Zoberi; Jose Garcia-Ramirez; Perry W Grigsby Journal: J Contemp Brachytherapy Date: 2017-10-30